IREB2

Across TCGA pan-cancer cohorts, IREB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IREB2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IREB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IREB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where IREB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.900	.005	36	view →
PDAC	OS	Median	IV	0.381	0.951	.006	30	view →
LUAD	DFS	Median	All	0.455	0.898	.002	14	view →
CCRCC	OS	Quartile	All	0.828	1.000	.004	9	view →
GBM	DFS	Tertile	All	0.704	0.861	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IREB2–UCEC (OS)

Open the UCEC breakdown →